Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.1%. By the end of trading, Regeneron Pharmaceuticals rose $7.01 (2.1%) to $339.51 on average volume. Throughout the day, 1,162,824 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 935,600 shares. The stock ranged in a price between $327.02-$341.34 after having opened the day at $328.09 as compared to the previous trading day's close of $332.50. Other companies within the Drugs industry that increased today were: Fate Therapeutics ( FATE), up 28.8%, Dendreon ( DNDN), up 14.9%, Cara Therapeutics ( CARA), up 12.7% and DepoMed ( DEPO), up 11.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $33.1 billion and is part of the health care sector. Shares are up 20.8% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share.

On the negative front, RXi Pharmaceuticals ( RXII), down 11.7%, Synageva BioPharma ( GEVA), down 11.6%, NewLink Genetics ( NLNK), down 11.6% and Northwest Biotherapeutics ( NWBO), down 10.3% , were all laggards within the drugs industry with Merck ( MRK) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

Oil Stocks Jump as Global Crude Oil Rally Gains Steam

Oil Stocks Jump as Global Crude Oil Rally Gains Steam

P&G Tops Forecasts in Early Q3 Earnings Release Following Merck KGaA Deal

P&G Tops Forecasts in Early Q3 Earnings Release Following Merck KGaA Deal

Amazon Prime Tops 100 Million Members and 4 Other Stories You Must Know Thursday

Amazon Prime Tops 100 Million Members and 4 Other Stories You Must Know Thursday